CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Trial

Event summary

  • CytoDyn has completed enrollment in its Phase 2 CLOVER study for metastatic colorectal cancer (mCRC), with 60 patients across 7 U.S. clinical sites.
  • The trial evaluates leronlimab in combination with TAS-102 and bevacizumab in CCR5-positive, microsatellite stable (MSS) mCRC patients.
  • Primary endpoint is objective response rate (ORR) per RECIST v1.1 criteria, with secondary endpoints including safety, duration of response, and overall survival.
  • Preliminary data from ongoing Phase 2 mCRC program showed early signals of clinical and biomarker activity, including reductions in circulating tumor DNA.

The big picture

CytoDyn's completion of enrollment in this Phase 2 trial represents a critical step in validating CCR5 inhibition as a therapeutic strategy in mCRC. The study's focus on MSS patients—a particularly challenging subset with high unmet need—positions leronlimab to potentially carve out a niche in an oncology market increasingly dominated by immunotherapy combinations. Success here could bolster CytoDyn's pipeline valuation, though the company will need to demonstrate clear clinical benefits to compete with established and emerging treatments.

What we're watching

Clinical Efficacy
Whether leronlimab's combination therapy can demonstrate meaningful improvement in ORR and overall survival in this refractory patient population.
Regulatory Pathway
How topline data from this Phase 2 study may inform CytoDyn's strategy for potential future registrational trials or regulatory discussions.
Competitive Positioning
The pace at which CytoDyn can differentiate leronlimab in the crowded mCRC treatment landscape, particularly for MSS patients with limited options.